Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debora Degl'Innocenti

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Cancer Letters|May 27, 2008
Inflammation and cancer: the oncogene-driven connectionMaria Grazia Borrello, Debora Degl'Innocenti, Marco A Pierotti
Molecular Endocrinology (Baltimore, Md.)|January 13, 2004
Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's diseaseElena Arighi, Anna Popsueva, Debora Degl'Innocenti, et al.
Neoplasia (New York, N.Y.)|December 25, 2008
RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocationGiuliana Cassinelli, Enrica Favini, Debora Degl'Innocenti, et al.
Biochemical and Biophysical Research Communications|August 15, 2002
Differential interaction of Enigma protein with the two RET isoformsMaria Grazia Borrello, Elena Mercalli, Carla Perego, et al.
Journal of Hematology & Oncology|April 14, 2016
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patientsCinzia Pellegrini, Anna Dodero, Annalisa Chiappella, et al.
Clinical Endocrinology|May 8, 2010
The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studiesMarina Muzza, Debora Degl'Innocenti, Carla Colombo, et al.
Plos One|September 30, 2010
Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomasDebora Degl'Innocenti, Chiara Alberti, Giancarlo Castellano, et al.
Oncogene|August 25, 2004
Differential requirement of Tyr1062 multidocking site by RET isoforms to promote neural cell scattering and epithelial cell branchingDebora Degl'Innocenti, Elena Arighi, Anna Popsueva, et al.
Oncotarget|May 10, 2014
miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinomaEmanuela Minna, Paola Romeo, Loris De Cecco, et al.
Endocrine-Related Cancer|November 8, 2012
DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cellsDebora Degl'Innocenti, Paola Romeo, Eva Tarantino, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cancer Letters|May 27, 2008
Inflammation and cancer: the oncogene-driven connectionMaria Grazia Borrello, Debora Degl'Innocenti, Marco A Pierotti
Molecular Endocrinology (Baltimore, Md.)|January 13, 2004
Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's diseaseElena Arighi, Anna Popsueva, Debora Degl'Innocenti, et al.
Neoplasia (New York, N.Y.)|December 25, 2008
RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocationGiuliana Cassinelli, Enrica Favini, Debora Degl'Innocenti, et al.
Biochemical and Biophysical Research Communications|August 15, 2002
Differential interaction of Enigma protein with the two RET isoformsMaria Grazia Borrello, Elena Mercalli, Carla Perego, et al.
Journal of Hematology & Oncology|April 14, 2016
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patientsCinzia Pellegrini, Anna Dodero, Annalisa Chiappella, et al.
Clinical Endocrinology|May 8, 2010
The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studiesMarina Muzza, Debora Degl'Innocenti, Carla Colombo, et al.
Plos One|September 30, 2010
Integrated ligand-receptor bioinformatic and in vitro functional analysis identifies active TGFA/EGFR signaling loop in papillary thyroid carcinomasDebora Degl'Innocenti, Chiara Alberti, Giancarlo Castellano, et al.
Oncogene|August 25, 2004
Differential requirement of Tyr1062 multidocking site by RET isoforms to promote neural cell scattering and epithelial cell branchingDebora Degl'Innocenti, Elena Arighi, Anna Popsueva, et al.
Oncotarget|May 10, 2014
miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinomaEmanuela Minna, Paola Romeo, Loris De Cecco, et al.
Endocrine-Related Cancer|November 8, 2012
DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cellsDebora Degl'Innocenti, Paola Romeo, Eva Tarantino, et al.
Pageof 2